Increased understanding of the ability of Klf4 to inhibit Cyp17A1 production may suggest a target for overcoming the molecular aberrations underlying hyperandrogenic disorders such as PCOS. This evidence concerns the gene CYP17A1 and polycystic ovary syndrome.